Jefferies Financial Group Inc. Buys New Position in Elanco Animal Health Incorporated (NYSE:ELAN)

Jefferies Financial Group Inc. bought a new position in Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) in the fourth quarter, according to the company in its most recent filing with the SEC. The fund bought 80,899 shares of the company's stock, valued at approximately $980,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of the stock. Steward Partners Investment Advisory LLC boosted its holdings in Elanco Animal Health by 28.3% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 10,264 shares of the company's stock valued at $124,000 after acquiring an additional 2,264 shares during the period. DDD Partners LLC purchased a new position in Elanco Animal Health during the 4th quarter valued at $5,974,000. Dimensional Fund Advisors LP boosted its holdings in Elanco Animal Health by 6.4% during the 4th quarter. Dimensional Fund Advisors LP now owns 17,900,987 shares of the company's stock valued at $216,774,000 after acquiring an additional 1,074,274 shares during the period. Jones Financial Companies Lllp boosted its holdings in Elanco Animal Health by 95.6% during the 4th quarter. Jones Financial Companies Lllp now owns 4,212 shares of the company's stock valued at $51,000 after acquiring an additional 2,059 shares during the period. Finally, Private Management Group Inc. boosted its holdings in Elanco Animal Health by 63.4% during the 4th quarter. Private Management Group Inc. now owns 2,357,142 shares of the company's stock valued at $28,545,000 after acquiring an additional 914,808 shares during the period. Hedge funds and other institutional investors own 97.48% of the company's stock.

Insider Transactions at Elanco Animal Health

In other Elanco Animal Health news, Director Lawrence Erik Kurzius bought 10,000 shares of Elanco Animal Health stock in a transaction that occurred on Tuesday, March 11th. The shares were bought at an average cost of $10.20 per share, with a total value of $102,000.00. Following the transaction, the director now directly owns 111,459 shares of the company's stock, valued at approximately $1,136,881.80. This represents a 9.86% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 0.89% of the company's stock.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on the company. Barclays dropped their price objective on Elanco Animal Health from $20.00 to $19.00 and set an "overweight" rating for the company in a report on Wednesday, February 26th. UBS Group lowered their target price on Elanco Animal Health from $18.00 to $17.00 and set a "buy" rating for the company in a report on Wednesday, February 26th. Stifel Nicolaus upped their target price on Elanco Animal Health from $15.00 to $16.00 and gave the stock a "buy" rating in a report on Monday, May 19th. Piper Sandler lowered their target price on Elanco Animal Health from $16.00 to $12.00 and set a "neutral" rating for the company in a report on Thursday, March 6th. Finally, Morgan Stanley lowered their target price on Elanco Animal Health from $14.00 to $13.00 and set an "equal weight" rating for the company in a report on Wednesday, February 26th. Four analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to MarketBeat, Elanco Animal Health currently has a consensus rating of "Hold" and an average price target of $15.17.

Elanco Animal Health Stock Down 0.0%

Shares of ELAN stock traded down $0.01 during mid-day trading on Monday, hitting $13.44. The stock had a trading volume of 5,226,290 shares, compared to its average volume of 5,117,256. Elanco Animal Health Incorporated has a 12-month low of $8.02 and a 12-month high of $18.80. The firm has a market capitalization of $6.67 billion, a P/E ratio of 33.59, a price-to-earnings-growth ratio of 2.50 and a beta of 1.49. The firm's 50-day moving average is $10.66 and its two-hundred day moving average is $11.39. The company has a debt-to-equity ratio of 0.66, a current ratio of 2.55 and a quick ratio of 1.31.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The company reported $0.37 EPS for the quarter, topping the consensus estimate of $0.31 by $0.06. The firm had revenue of $1.19 billion during the quarter, compared to analyst estimates of $1.17 billion. Elanco Animal Health had a return on equity of 6.78% and a net margin of 4.60%. The business's revenue for the quarter was down 1.0% compared to the same quarter last year. During the same period in the previous year, the company posted $0.34 EPS. On average, analysts predict that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current fiscal year.

Elanco Animal Health Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.